The Early Outpatient COVID-19 Plasma Treatment Research Study (CSSC-004) has been named a finalist for the 2023 Clinical Research Achievement Awards. The Clinical Research Achievement Awards is sponsored by the Clinical Research Forum, and it honors those who demonstrate a commitment to excellence and innovation in clinical research. This awards program seeks to recognize research that significantly advances the health and welfare of our nation’s citizens. Finalists are among the top 20 studies nominated nationwide.
The CSSC-004 trial assessed the efficacy and safety of convalescent plasma to reduce the risk of hospitalization or death, the duration of symptoms, and duration of viral shedding through nasal and oral secretions. The study was led by researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health with support and coordination from BIOS CTCC. The primary outcome data show that plasma from patients whose blood contains antibodies against SARS-CoV-2 is a safe and effective early outpatient treatment for COVID-19. Results were published in The New England Journal of Medicine.